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Abstract: Cancer is a complex devastating disease with enormous treatment challenges, including chemo-
and radiotherapeutic resistance. Combination therapy demonstrated a promising strategy to target hard-
to-treat cancers and sensitize cancer cells to conventional anti-cancer drugs such as doxorubicin. This
study aimed to establish molecular profiling and therapeutic efficacy assessment of chloroquine and/or
tioconazole (TIC) combination with doxorubicin (DOX) as anew combination model in MCF-7 breast
cancer. The drugs are tested against apoptotic/autophagic pathways and related redox status. Molecular
docking revealed that chloroquine (CQ) and TIC could be potential PI3K and ATG4B pathway inhibitors.
Combination therapy significantly inhibited cancer cell viability, PI3K/AkT/mTOR pathway, and tumor-
supporting autophagic flux, however, induced apoptotic pathways and altered nuclear genotoxic feature.
Our data revealed that the combination cocktail therapy markedly inhibited tumor proliferation marker
(KI-67) and cell growth, along with the accumulation of autophagosomes and elevation of LC3-II and
p62 levels indicated autophagic flux blockage and increased apoptosis. Additionally, CQ and/or TIC
combination therapy with DOX exerts its activity on the redox balance of cancer cells mediated ROS-
dependent apoptosis induction achieved by GPX3 suppression. Besides, Autophagy inhibition causes
moderately upregulation in ATGs 5,7 redundant proteins strengthened combinations induced apoptosis,
whereas inhibition of PI3K/AKT/mTOR pathway with Beclin-1 upregulation leading to cytodestructive
autophagy with overcome drug resistance effectively in curing cancer. Notably, the tumor growth
inhibition and various antioxidant effects were observed in vivo. These results suggest CQ and/or TIC
combination with DOX could act as effective cocktail therapy targeting autophagy and PI3K/AKT/mTOR
pathways in MCF-7 breast cancer cells and hence, sensitizes cancer cells to doxorubicin treatment and
combat its toxicity.
Keywords: autophagy; apoptosis; PI3K; tioconazole; chloroquine; doxorubicin
1. Introduction
Cancer is one of the major killers and causes of death worldwide, similar to cardio-
vascular diseases [1]. Resistance to chemotherapeutic compounds is one of the significant
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obstacles to the successful treatment of various human cancers. Thus, the elucidation of the
mechanisms involved in drug resistance and new strategies to re-sensitize cancer-resistant
cells are key elements in generating improved therapies [2]. Apoptosis and autophagy are
types of programmed cell death (PCD) that play a crucial role in maintaining organismal
and cell homeostasis quality control mechanisms. Additionally, it was regarded as a bona
fide PCD process involved in the chemotherapy-induced cell death mechanism.
Apoptosis is regulated by intracellular and/or extracellular signals; hence, the cas-
pase’s activation is considered a potential therapeutic target against human cancer dis-
eases [3]. Autophagy is a major pathway in all eukaryotic cells and is considered as a
multistep process in which cytoplasm, intracellular organelles, and proteins are sequestered
through the fusion of autophagosomes with lysosomes forming autolysosomes, with ul-
timate degradation by lysosomal hydrolases, while autophagy has a crucial role as an
emerging cell survival process [4].
Several studies demonstrated insights on mutual aspects between autophagy and
apoptosis, describing a complicated crosstalk/interplay between both processes which
play profound roles in cancer chemoprevention [5]. Several strategies of cancer therapy
target the autophagy pathway, which promotes tumorigenesis in the advanced stage via a
recycling mechanism that is vital to tumor progression [6], while the inhibition of autophagy
increases tumor cell death and sensitized cells to some chemotherapeutic drugs [7,8].
Activation of PI3K/AKT/mTOR plays a crucial role in cell proliferation, apoptosis,
and autophagy in breast cancer [9]. Moreover, activation of AKT and AMPK-related sig-
naling pathways trigger autophagy, while extensive studies indicate that the upregulated
autophagy enhances tumor survival and enhances the drug resistance of tumors in a
wide range of tumor types. It has been stated that the main downstream of PI3K/AKT
leads to autophagy inhibition. Thus, the combination of PI3K inhibition with autophagy
inhibition can achieve a more potent anti-tumor effect and cell cycle-mediated drug resis-
tance [10]. Therefore, crosstalk between autophagy inhibition and apoptosis-induction in
many cancer cells is considered a therapeutic strategy to sensitize tumor cells and overcome
resistance. Other findings suggest autophagy inhibition as a potential strategy to enhance
the therapeutic efficacy of dual PI3K/mTOR inhibitor in cancer treatment [11].
Activation and inhibition of the PI3K/AKT pathway have been elucidated to regulate
human cancer cell survival in vitro [12] and in vivo regulation of tumorigenicity, invasion,
and metastasis [13]. Therefore, the PI3K/AKT pathway has shown to be a promising
therapeutic target to induce apoptosis [14]. A recent study reported that dual PI3K/mTOR
inhibition (DKI) strongly inhibits autophagy in the late stage due to the class-III PI3K
Vps34 inhibition, which suggested this dual inhibition of PI3K/mTOR causes blockage of
autophagosome-lysosome fusion resulting in decreased autophagic flux and accumulations
of non-degraded autophagosomes [15]. The dual inhibition of PI3K and mTOR abolished
this protein phosphorylation. This observation is consistent with a dual role of the AKT,
which is well known to suppress autophagy through inhibition, and increasing mitochon-
drial superoxide and ROS. Otherwise, the accumulation events often lead to mitochondrial
disorder, accompanied by cytochrome C’s release [16].
Doxorubicin (DOX) is the commonest chemotherapy used against various types of
metastatic cancers; it is needed to be combined with another highly effective non-toxic
agent to reduce its toxicity and modulate different signaling pathways in cancer cells and
enhance anti-tumor efficacy [17].
Recently, Fabi et al.’s study demonstrated that AKT inhibitors with DOX as a novel
therapeutic combination strategy have a potential role in sensitizing cancer cells to DOX,
which allows the upregulation of pro-apoptotic proteins the coordinated downregulation
of anti-apoptotic regulators [18].
Chloroquine (CQ) is an anti-malarial drug and a lysosomotropic agent, and has
demonstrated cytotoxic effects against various types of human cancers via stimulating
cell-cycle arrest, inhibiting autophagy and ultimate apoptosis of tumor cells, along with
its ability to increase sensitization of different therapeutic modalities that are used in
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chemotherapy cancer treatment [11]. Additionally, CQ has been reported to increase the
drugs’ intracellular targets by inhibiting the autophagic cargo degradation, and it is used in
combination with other chemotherapies as an effective cancer-specific chemosensitizer [19].
Previous studies reported that the combination of CQ/DOX has been demonstrated
to effectively sensitize MCF-7 to DOX [20]. Co-encapsulated DOX and CQ liposomes were
revealed as a promising formulation for treating DOX-resistant MCF-7 breast cancer by
protecting DOX from effluxing outside of cancer cells [21]. Recently, Guo et al. demon-
strated that acquisition of DOX resistance may be associated with autophagy induction in
breast cancer since blockage of autophagy restored sensitivity to DOX [22]. Tioconazole
(TIC) is an anti-fungal drug. It has recently been reported as a potential anticancer drug
either in combination with DOX or Camptothecin (CPT) by inhibiting ATG4B activity and
autophagic flux impairment, suggesting its role anticancer drug or chemosensitizer [23].
The current studies showed that autophagy blockage using combination therapy is an
emerging model in cancer treatment and could sensitize cancer cells to investigational ther-
apeutics; hence, autophagy blockage may enhance the pro-apoptotic effects of PI3K/mTOR
inhibitors in preclinical studies [16,24] and it is evident that our results support the latter.
It is based on the evidence that tumor cells upregulate autophagy to mitigate anticancer
agents’ deleterious effects [25]. Thus, the quest for new drug combinations that can in-
crease or sustain effectiveness, minimize toxicity, and postpone drug resistance growth
is essential.
Therefore, we hypothesized that CQ/TIC combination can be used as a neoadjuvant
to DOX to improve its therapeutic efficacy and reducing its adverse effects. Our main
goal was to investigate the putative underlying mechanisms of crosstalk of proliferation,
autophagic and apoptotic machinery in cancer cells treated with DOX with CQ and/or
TIC. Apoptotic pathway markers (Comet assay, DNA fragmentation assay, Bax, Bcl-2, p53,
caspase-3, 8, 9, and cytochrome C), autophagic pathway markers (ATG4B, ATG5, ATG7,
LC-3, and p62), and proliferating markers (PI3K/AKT/mTOR signaling and KI-67) were
investigated in vitro and in vivo.
Our study showed extensive efforts to enhance chemotherapy’s efficacy and inves-
tigate synergistic drug combinations for cancer therapy. The main goal is to have a safe
starting point; the results demonstrate that the combination of CQ/TIC/DOX induces a
more significant anti-tumor effect than each drug alone in the MCF-7 breast cancer cell line.
This combination model of CQ/TIC/DOX demonstrated that combined treatment could be
advantageous for cancer therapy than DOX alone, which is too toxic. These results should
be confirmed in using further cancer models and may be significant clinically. These data
may lead to new therapeutic strategies for MCF-7 breast cancer therapy.
2. Results and Discussion
Programmed cell death pathways such as apoptosis and autophagy-related to tumor
formation and development can be invaded by various strategies as potential therapeutic
targets against cancer disease; crosstalk between both pathways in cancer cells has been pre-
viously described [26]. Previous studies have reported that autophagy inhibition strategies
promote cell death in cancer cells which are resistant to many anticancer therapies and may
also be able to retrieve the sensitivity of those therapies [27]. Consequently, the late stage
of autophagy usually contributes to the fusion of autophagosomes with lysosomes or the
autolysosomes degradation. In contrast, the autophagosomes are implicated as scaffolds to
induce apoptosis, which might be exploited as a potential cancer therapy target [28].
Additionally, several studies reported that multi-targeted drugs are preferred in
clinical trials while they seek to maximize the chance for clinical anti-tumor activity [29].
Of note, the combination drugs strategy has recently attracted much attention as promising
therapeutic tools to fight against the most challenging diseases. Thus, a new research area
allows the molecular recognition of more than one bioreceptor, acting simultaneously on
multiple interconnected targets to biochemical networks [30].
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Moreover, several reports have indicated that autophagy inhibition synergizes chemo-
therapy’s effect to induce tumor cell death. Hence, we deduced that the development
of more effective and autophagy inhibitors is a very active and precise research area
suggesting that the anti-tumor effect can be achieved via multiple mechanisms elicited
when using combination therapy.
Our study focused on combination therapy as a multi-target that aims to reduce drug
dose and toxicities to attain synergistic effect and cope with some anticancer therapies’
resistance, understanding mechanisms of the combinatorial drugs sparked in combination
therapy regimens. We provided a new combinatorial therapeutic strategy to identify the
synergistic therapeutic effect of DOX with CQ and/or TIC that simultaneously targets
PI3K, ATG4B, and lysosome to inhibit autophagy through apoptosis dependent manner,
potentially serving as promising anti-cancer agents. In surprising, our findings showed
that DOX with CQ and/or TIC combinatory treatment decreases the activation of the
PI3K/AKT/mTOR and ATG4B pathways, led us to investigate the possible synergistic
mechanism between those multi-targeted drugs that dramatically affect cancer cells prolifer-
ation, and induced ROS production, and ultimate apoptosis. It was reported that activation
of PI3K/AKT signaling pathways has a crucial role in modulating cancers’ development
and progression, contributing to the resistance to anti-cancer agents [31].
2.1. In Silico Molecular Docking Analysis of Selected FDA Approved Drugs against ATG4B and
PI3K (α, γ Isoform)
The molecular docking results showed that TIC has the most favorable binding inter-
action on ATG4B (PDB ID: 2Z0D) with the estimated free energy of binding−6.10 kcal/mol,
and inhibition constant (Ki) 33.75 nM, while CQ with the estimated free energy of binding
−4.36 kcal/mol, and inhibition constant (Ki) 637.60 uM. However, DOX with the estimated
free energy of binding +11.57 kcal/mol (Table 1) Simultaneously, all docking complexes of
ATG4B (2Z0D) are dominated by hydrophobic interactions (Figure 1I). Molecular docking
analysis data showed new anti-cancer suggestions of existing drugs that exhibited that TIC
and CQ bind to ATG4B and TIC as a potent inhibitor for ATG4B that consistent with the
previous study [23] that showed TIC inhibits autophagic flux. Hence, we described CQ as
a docked ATG4B catalytic subunit with moderate binding energy than TIC or DOX.
Table 1. Results of the docking of FDA-approved drugs and the interactions constructed on the crystal structure of ATG4B
(PDB ID: 2Z0D).
Compound













ATG4B Take Part in
the Interaction
TIC −6.10 33.75 2 ASN 84 and TYR 110 2 LYS 8 and VAL 112
CQ −4.36 637.60 4 LEU 82, ASN 84, GLY85 and VAL 112 7
LYS 8, ILE 34, GLU 36,
LEU 82, TYR 110 (2)
and VAL 112 and
GLU 36
DOX +11.57 – 5 LYS 8, LYS 39, ASN 84,GLY 85 and ASP104 5
THR 6, LYS 8, TYR 38
and VAL 112 (2)
Note: Salt Bridges residues represent through the Italic bold residue.
Otherwise, the results of molecular docking analysis of PI3Kα (p110α, ID: 2RD0) that
represent phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha contain-
ing nSH2 domain mediates PI3K functions through a-loop dynamics. TIC has the most
favorable binding interaction with the estimated free energy of binding −8.99 kcal/mol,
and inhibition constant (Ki) 257.99 nM, while CQ with the estimated free energy of binding
−6.67 kcal/mol, and inhibition constant (Ki) 12.86 uM that are previously reported to have
a potent inhibition effect on autophagy. However, DOX with the estimated free energy of
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binding−7.45 kcal/mol and inhibition constant (Ki) 3.48 µM. Otherwise, we reported seven
H-bonds and four H-bonds in DOX and CQ interaction profiles, respectively (Table 2).
Figure 1. The predicted conformation docking of doxorubicin (DOX), Chloroquine (CQ), and tioconazole (TIC) in complex
with ATG4B, PI3Kα isoform and, PI3Kγ isoform. The binding models obtained from the docking simulation analysis of
TIC (A), CQ (B), DOX (C) selected drugs against ATG4B (PDB 2Z0D) (I), PI3Kα (p110alpha/p85) catalytic subunit (PDB
2RD0) (II) and PI3Kγ kinase (PDB 1E8X) (III). The ligands (drugs) are represented as an orange stick, and the active site
residues in the expanded panels are represented in blue sticks while interacting residues are in lines and labeled with their
three-letter code. Structures of all proteins are shown as cyan-colored ribbon surface model, and H-bonds and hydrophobic
interactions are shown by a blue line and dashed-gray line, respectively.



















TIC −8.99 0.25799 0 - 1 HIS 670
CQ −6.67 12.86 5
GLN 630, LEU 755,
GLN 815 and ARG
818 (2)
4
ILE 633, PHE 666,
LEU 814
and GLN 815
DOX −7.45 3.48 7
ASP 626, HIS 670,
LEU 755, MET 811,






Note: Salt Bridges residues represent through the Italic bold residue and π-Stacking (parallel) residues represent through the bold residue.
Protein-Ligand Interaction Profiler (PLIP) analysis showed the hydrogen interactions
are dominant in all PI3K protein docked complexes (Figure 1II). Interestingly, TIC binding
residue shows that π-stacking interaction is constructed with HIS 670, as previously re-
ported, the π-stacking interaction of aromatic rings is a well-known type of intermolecular
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interaction, which refers to attractive, noncovalent interactions between aromatic rings
that allow not only to reinforce the mutual interactions but also to generate the emergent
intermolecular communications [32], also this type of interaction recognized to have a
crucial role in the thermal stability and folding of proteins and the binding to ligands [33].
The other molecular docking of interaction on PI3Kγ structure with the ATP bind-
ing site (ID: 1E8X) representing phosphoinositide 3 kinase catalytic subunit is part of
PI3K/AKT/mTOR pathway. Data showed that TIC has the most favorable binding inter-
action to the ATP-binding pocket of PI3K through a hydrogen bond and a halogen bond
with the estimated free energy of binding −9.10 kcal/mol, and inhibition constant (Ki)
215.23 nM, while CQ with the estimated free energy of binding −6.23kcal/mol, and inhibi-
tion constant (Ki) 27.09 uM that are previously reported to have a potent inhibition effect
on autophagy. However, DOX with the estimated free energy of binding −7.65 kcal/mol
and inhibition constant (Ki) 2.47 uM (Table 3).



















TIC −9.10 0.21523 1 LYS 890 3
LYS 833, ILE 879,
ILE 963
and TYR 867
CQ −6.23 27.09 4 LYS 833, TYR 867(2)and ASP 964 8
ILE 831, LYS 833,
TYR 867, ILE 879(2),
ILE 963 (2), ASP
964 and ASP 836,
ASP 964
DOX −7.65 2.47 5
ALA 805, LYS 807,
LYS 833, ASP 836
and ASP 964
2 ILE 831, 879 andLYS 807
Notes: Salt Bridges residues represent through the Italic bold residue and π-Stacking (parallel) residues represent through the bold residue.
PLIP analysis showed the hydrogen interactions are dominant in all PI3Kγ protein
docked complexes in DOX protein interaction (Figure 1III). Interestingly, most residues
are predominantly non-hydrophobic, whereas all docking complexes are dominated by
hydrophobic interactions in TIC and CQ binding residues. Remarkably, the π-Stacking
interaction is constructed with TYR 867. So, we thought that TIC might be a potent
inhibitor of PI3K due to the primary pharmacological structure of TIC is an imidazole
ring similar to the structure of Econazole, as imidazole antifungal that recently docked
PI3K by −7.3 kcal/mol that diminished P-AKT and Bcl2 protein levels [34]. In our in-silico
study, the molecular docking approach was used to study the molecular affinity of TIC
with autophagic related proteins ATG4B and PI3Kα, γ isoforms compared to CQ and DOX.
2.2. Cytotoxic and Synergistically Effect of DOX, CQ, and TIC by Single and Combination Treatment
MTT assay was applied to evaluate the cytotoxic effect of single treatment with
different concentrations of CQ, TIC, and DOX on the proliferation of MCF-7 cells and
control WISH cells as well. IC50s values were obtained at 32.5, 14.5, and 3.38 µM for CQ,
TIC, and DOX, respectively on MCF-7 and at 85.05, 73.62, 13.7 µM respectively on WISH
cells (Figure 2I-(A–C)).
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Figure 2. Growth inhibition and aggressiveness of cancer cells assessment. The dose-response inhibition concentration
was estimated via MTT assay Plot curve that showing IC50 values of every single DOX, CQ, and TIC treatment on human
normal epithelial cells (WISH) cells (I-A), MCF-7 cells (I-B), and IC50 values of combinatorial therapies ratios of DOX, CQ,
and TIC that achieved best combination Index (CI < 1) with a highest toxic effect on MCF-7 breast cancer cells (I-C). The
cell viability was plotted against drug concentration to calculate IC50 and each data point represents an average of three
independent experiments (n = 3). Growth curve for tumors of MC-7 tumor-bearing xenograft mice, with points representing
mean tumor volumes in each group of mice (II-A), Bare diagram represent the dramatical difference point change of mean
tumor volumes in each group of mice (II-B), Average survival time per each group of MCF-7 mice model (II-C). Results are
expressed as mean ± SE (n = 3). # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001 compared with control (MCF-7-mice
untreated group). + p < 0.05, ++ p < 0.01, +++ p < 0.001, ++++ p < 0.0001 compared with the DOX treated mice group.
We analyzed the nature of drug–drug interaction with a combination index (CI) using
CompuSyn Software. Regarding MCF-7 cells, the constant combinations of double or
triple individual concurrent treatment showed an increase in the percentage of cell death,
especially in the triple combination treatment compared to either single agent. Additionally,
the synergistic cytotoxicity was observed in multiple combination ratios (Data not shown).
On the other hand, IC50s of best-selected combination treatment ratio were obtained at 2.67,
2.3, and 3.2 µM for DOX-CQ (1:2), (DOX-TIC 1:6), and (DOX-TIC-CQ (1:1:1). Interestingly,
those IC50s values are less than IC50 of DOX alone (3.38 µM).
We observed synergistic relationships (CI ≤ 1) in the following combinations: DOX-
CQ (1:2), (DOX-TIC 1:6) and (DOX-TIC-CQ (1:1:1), with CI value of 0.256, 0.540 and 0.530,
respectively on MCF-7 cells. The cytotoxic effect at ED50 killing cancer cell, TIC or CQ
has a highly cytotoxic effect in combination to be considered highly anticancer agents,
while that of DOX continued to gradually decrease and showed synergistic activity when
>90% of MCF-7 cells were inhibited. Herein, we showed a strong synergism of DOX
with CQ and/or TIC against MCF-7 cells (Supplementary Table S1 and Figure S1). These
results encouraged us to continue biological investigations on such combinations with
the mentioned ratios. At the same time, we try to understand the targeted mechanism of
combination treatments and investigate the crosstalk and mechanistic effects by assessing
apoptotic and autophagy analysis.
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Additionally, we investigated the anti-tumor efficacy of combinatorial treatment of
DOX with CQ and/or TIC against the MCF-7 xenograft model. Our results showed
that combinatorial treatments of DOX with CQ and/or TIC had a strong anti-tumor
effect against MCF-7 tumor mice. The MCF-7 xenograft mice model’s tumor volume
was significantly decreased in all treated groups compared to control. Additionally, the
increased rate of tumor inhibition of mammary tumor growth was observed in all treated
groups, maximum inhibition rate especially in triple combinations (Figure 2II-(A,B)).
Therefore, we observed that the combinatorial treatments of DOX with CQ and/or TIC
increased MST (25~30 days), ILS% (60~90%) of MCF-7 tumor inoculated mammary mice
when compared with untreated mice than either compared with control or dox treated
groups (Figure 2II-C). This is consistent with a study that reported the combinatorial
treatments to be more effective as a significant reduction in tumor size with a prolonged
life span, which was a significant criterion in determining the anticancer compound’s
effectiveness [35].
2.3. Genotoxic Apoptotic Features
The cytotoxic effect of tested drugs was further evaluated on a molecular level using
comet assay and DPA colorimetric assay to determine percentages of cellular DNA frag-
mentation. Our comet assay data showed a moderate significant DNA damage in DOX,
CQ, and TIC single treated groups. Furthermore, DOX combination with CQ and/or TIC
demonstrated DNA damage compared to the untreated group. The triple combinatorial
therapy showed extensive DNA damage more than DOX treated cells, where the staining
intensity and length of the comet tails reflect the DNA damage degree that confirmed the
damage of nuclear DNA of tumor cell through the accumulative induction of single and
double DNA stranded breaks when the alkaline comet assay detected both single and
double-stranded DNA breaks (Figure 3I-A,II-(A,B)).
Figure 3. The effect of DOX, CQ, and TIC single or combinations treatments on DNA Damage. Comet assay represents
genotoxicity of selected single or combined drugs causing nuclear DNA Damage and photomicrographs of MCF-7 cells
(I-A) and MCF-7 Xenograft mice (II-A). Computed comet tail length (µm) representing DNA damage in MCF-7 cells (I-B)
or MCF-7 Xenograft mice (II-B). The percent of fragmented DNA measured colorimetric using Diphenylamine reagent
estimated in all treated groups of MCF-7 cells (I-C) and MCF-7 Xenograft mice (II-C). Results are expressed as mean ± SE
(n = 3). # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001 compared with control (untreated group). + p < 0.05, ++ p < 0.01,
+++ p < 0.001, ++++ p < 0.0001 compared with the DOX treated group.
Moreover, DPA results showed to be in agreement with comet assay results where
% of cellular DNA fragmentation profiles was higher in combination treatments with
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fewer changes observed than DOX alone. These results indicated that those combinations
induced cancer growth inhibition via apoptosis (Figure 3I,II-C). Congruently, in vitro and
in vivo studies were consistent. Eventually, this result highlighted CQ/or TIC’s impact on
sensitizing breast cancer cells to apoptotic effect, which is induced by DOX as evidenced
by comet and DNA fragmentation assays.
Our study reported that imidazole derivative drug TIC alone or in combinations
exhibited the highest genotoxicity that matched with a previous study [36] which reported
the genotoxic effect of imidazole derivatives (highest % of tail length DNA damage), along
with the toxic effect of single DOX [37] and CQ [38]. Whereas DOX combination with CQ
and/or TIC caused DNA damage, possibly through distinct but overlapping mechanisms,
DNA fragmentation was observed in combinatorial treatments, confirming cell death
through the apoptotic pathway [35,39].
2.4. Detection of Cell Death Using Annexin V/PI Double Staining
This assay was performed to examine the nature of the cytotoxic effect of combinatorial
drugs DOX either with CQ and/or TIC in vitro and in vivo (Figure 4I,II).
Figure 4. Effect of DOX, CQ and TIC single or combination treatments on the apoptotic cell population. Flow cytometric
analysis showed AnnexinV-FITC/PI stained of MCF-7 cells (I-A) and MCF-7 Xenograft mice (II-A) treated with single or
combinatorial treatments. In each panel, the lower and upper left quadrants represent the percent of viable and the dead
cells, respectively. The lower and upper right quadrants represent the percent of early and late apoptotic cells, respectively.
Bar diagram showing means % of apoptotic cell numbers of MCF-7 cells (I-B) and MCF-7 Xenograft mice (II-B) treated with
single or combinatorial treatments. Values are expressed as mean ± SE (n = 3). Means within columns carrying symbols
are significantly different. # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001 compared with control (untreated group).
+ p < 0.05, ++ p < 0.01, +++ p < 0.001, ++++ p < 0.0001 compared with the DOX treated group.
Our data revealed a progressive increase in the percentage of apoptotic cells in the
combined treatment groups. Results showed that the number of early and late apoptotic
cells was significantly increased in cells treated with the combination of DOX/CQ and/or
TIC compared to untreated or single DOX treated groups. However, the percentage of
late apoptotic and necrotic cells is also high in all those combinations. All combinatory
treated mice groups showed highly apoptotic features, triggering early and late apoptosis
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phases. These data were matched with a previous study, which reported that apoptotic
cells’ presence resulted from apoptosis rather than necrosis [40].
Yet, the synergistic interaction between DOX with CQ and/or TIC against cancer cells
could clearly be explained by the excessive increase of apoptotic cell fraction compared
to a single treatment consistent with Liu and his colleagues. They reported that early
apoptosis could be induced due to a dual combination of DOX either with CQ or TIC [23].
It is noteworthy that our data exhibited double and triple combination treatments induced
extensively early and late apoptosis compared to single treatments alone, which might
bypass apoptosis pathways.
2.5. Assessment of Autophagy Features
Results showed that an increase in the autophagosome levels indicates autophagic flux
inhibition exerted by CQ and/or TIC treatment with or without DOX attributed to blockage
the late stage of autophagy reflecting the accumulation of the autophagosome numbers
(Figure 5 and Supplementary Figure S2) significantly. Intriguingly, all combinations that
showed a strong synergistic effect to induce autophagic death of tumor cells may be
attributed to inhibition of autophagosome–lysosome fusion leading to accumulation of
autophagosomes/mitophagosomes with ultimate autophagic cell death of tumor cells.
These results were consistent with the previous study, which explored the advantage
of multiple cancer drugs over the individual and their ability to cause accumulation of
autophagosome, leading to intracellular ROS accumulation and subsequent cell death [41].
Figure 5. Autophagic flux blockage induces autophagosome accumulation. Bar diagram showing mean fluorescence
intensity (MFI) of autophagosome marker in MCF-7 cells (I-A) and MCF-7 Xenograft mice (II-A) treated with single or
combinatorial treatments that induced autophagic cell death, which was investigated by flow cytometry analysis. Bar
diagram showing relative flow cytometry level (%) representing Autophagy Activity Factor (AAF) of MCF-7 cells (I-B) and
MCF-7 tumor-bearing mice (II-B) treated with single or combinatorial treatments. Each value expressed as mean ± SE,
(n = 3). # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001 compared with control (untreated group). + p < 0.05, ++ p < 0.01,
+++ p < 0.001, ++++ p < 0.0001 compared with the DOX treated group.
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2.6. Dual Inhibition of Autophagic Flux and PI3K/AKT Pathway-Dependent Cell Apoptosis
Regarding mRNA expression levels of apoptotic related genes including; Bax, caspase-
3, caspase-9, cytochrome C, they were upregulated in the DOX with CQ and/or TIC, while
triple combinations showed maximum expression levels compared with both single treated
and untreated cells. Notably, p53 mRNA expression level was upregulated in single DOX
treated cells compared to other treated or untreated cells. Otherwise, the triple combined
treated groups exhibit upregulated p53 expression compared to DOX co-treated with CQ
or TIC groups. On the other hand, combinations that upregulated mRNA expression of
Beclin-1 and ATG-7, especially triple cotreatment therapy, attained maximum upregulation
mRNA expression levels as shown in in vitro and in vivo models (Figure 6I,II).
Figure 6. The fold change alternations in mRNA levels. Bar diagram showing mRNA levels fold change of MCF-7 cells
(I) and MCF-7 Xenograft mice (II) treated with single or combinatorial treatments relative to control. Bax, p53, caspase-3,
caspase-9, Cytochrome C, and Bcl2 as apoptotic and anti-apoptotic genes (A), Beclin-1, ATG7, PI3K, and AKT as autophagic
and growth proliferative signaling genes (B). Values are expressed as mean ± SE, n = 3. Data are presented as mean ± SE
(error bar) of at least three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared with
control (untreated -cells or -mice) groups.
Conversely, Bcl2 mRNA expression level was significantly downregulated in DOX
with CQ and/or TIC co-treated groups, while the most minimal expression in triple
combined treated groups. These results indicate that triple combined treatments induced
apoptosis via the intrinsic mitochondrial apoptotic pathway-dependent caspases. The
combinatorial treatments were more potent in inducing apoptosis than the single one.
These data, consistent with protein expression levels data measured by Western blotting,
showed that Bcl-2 protein levels were dramatically decreased, while Bax levels were
markedly elevated in combination-treated groups as compared to those in the untreated
or single treated groups in case combinations over single treatment. Overall, such data
revealed that the synergistic effects of DOX combinations with CQ and/or TIC were mainly
attributed to increasing cells apoptosis induced by CQ and TIC and sensitizing tumor
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cells to DOX as represented in results of in vitro and in vivo models (Figure 7I,II and
Supplementary Figure S4I,II).
Figure 7. Autophagy inhibition induces cell death-dependent apoptosis. Representative Western
blots of autophagic markers (LC3I/II) and p62, PI3K/AKT/mTOR pathway markers, apoptotic and
anti-apoptotic markers (Bax, Bcl-2), GPX3 (anti-oxidant marker) proteins expression levels of MCF-7
cells (I) and MCF-7 Xenograft mice (II) treated with single or combinatorial treatments.
We further elucidate the specific molecular pathways that induce autophagy in cells by
monitoring PI3K and AKT’s relative mRNA expressions as kinases and autophagy-related
genes in vitro and in vivo (Figure 6I,II).
Our data revealed downregulation PI3K and AKT expression gene levels in case
combinations over a single treatment. We suggested that CQ and/or TIC with DOX
treatments markedly induce apoptosis and autophagic cell death via downregulation of
the PI3K/AKT/mTOR signaling pathway.
Meanwhile, the mechanism of repressing DOX resistance in cancer cells may occur via
downregulation of the levels of p-AKT and p-mTOR, as well as PI3K levels, cooperatively
suppressing the activation of proteins within the AKT pathway resulting in synergistic
cytotoxicity that might be implicated in the synergism of CQ and/or TIC with DOX. Here,
these findings offered us new insight into the anti-tumor activity of CQ and/or TIC, and
its combination with DOX helped us understand the relationship between apoptosis and
autophagic death of cancer cells. These results revealed that TIC and/or CQ with DOX
may be an adjuvant combined therapy targeted PI3K/AKT pathway which is abnormally
activated in many different human sarcoma types and is considered a promising target for
cancer therapeutic intervention.
These findings may be consistent with previous studies that described combined
mTOR inhibitors with monotherapy, and several combinations with other agents, including
anthracyclines, are being investigated in sarcomas as DOX, or temsirolimus plus liposomal
DOX that act as combined therapy targeted PI3K/AKT/mTOR pathway in many types
of solid malignancies and its blockade represents an opportunity to improve outcomes in
poor-prognosis sarcoma [42,43].
PI3K/AKT/mTOR is considered a signaling pathway for cancerous cell survival and
is highly activated in various tumor tissues. The activity of PI3K is vital for the initiation
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of autophagy. AKT and mTOR are serine/threonine kinases that play crucial roles in cell
proliferation and differentiation. Both of them require phosphorylation at specific sites to be
fully activated [44]. Hence, AKT shows as the activated constituent state in various cancers
that induces phosphorylation of a wide range of end targets, and mTOR plays essential
roles in regulating many anabolic processes, including autophagy and cell survival [45].
Additionally, blot analysis data further revealed that PI3K, AKT, and mTOR’s phos-
phorylation levels markedly reduced in combination treatments over single treatment
(Figure 7I and Supplementary Figure S4I). These results confirmed that the combination
therapy can regulate the growth and aggressiveness of cancer cells by downregulation
of PI3K/AKT/mTOR signaling pathways that dramatically enhance DOX cytotoxicity to
breast cancer cells. Furthermore, TIC/CQ significantly suppressed MCF-7 tumor growth
in mice (Figure 7II and Supplementary Figure S4II).
Our findings suggest that TIC/CQ combination is a potential PI3K inhibitor and a
potential drug that can be used in breast cancer treatment alone or in combination with
DOX. The current data are consistent with Dong and his colleagues’ study that showed
that econazole (Imidazole derivative) induces apoptosis in lung cancer cells through the
PI3K/AKT signaling pathways. Hence, their data represented that p-AKT and p-PI3K
expression levels were downregulated entirely by econazole [46]. This in agreement with a
previous study that reported PI3K inhibitors combinations with doxorubicin exhibit better
efficacy than monotherapy due to their strong synergistic antiproliferative effect of those
combinations, via inducing PI3K/AKT signaling blockage, which in turn led to activate
caspase-3/7 and caspase-9 and changed the expression of several apoptosis-related gene
expression [47].
On the other hand, Microtubule-associated protein light chain 3 (LC3) is considered
the key protein involved in the cell’s autophagy process. In the current study, the cytosolic
form of LC3-I and the conjugate LC3 phosphatidylethanolamine conjugate (LC3-II) were
high in the combination of DOX with CQ/or TIC (Figure 7I), consistent with in vitro results.
Furthermore, triple combination therapy enhanced LC3-II accumulation as compared with
the untreated group, suggested blockade of autophagic flux due to autophagic degrada-
tion impairment (Figure 7II), we speculated that the synergistic effect of combinations of
anticancer drugs may cause inhibition of ATG4B, which in turn impair autophagosome-
lysosome fusion and then diminishes autophagic activity. The statistical approach to
protein quantification is shown in Supplementary Figure S4.
This is consistent with evidence reported previously that the LC3-II accumulation may
be associated with elevated pH or impaired protease activity in the lysosome or defective
degradation of LC3-PE on autophagosomal structures the suppression of ATG4B activity [48].
This result agreed with previous studies that reported the crucial role of ATG4B in autophago-
some elongation and maturation steps of autophagic regulation that involved cancer cell
differentiation and proliferation [49,50]. Therefore, ATG4B inhibition through the combina-
tion therapeutic strategy may serve as a new cancer therapeutic strategy tool to diminish
autophagic flux and enhance chemotherapeutic drugs’ anti-tumor effect.
p62 protein, known as sequestosome 1 (SQSTM1), is a scaffold protein of autophagic
vesicles present in the polyubiquitinated protein aggregates to the lysosome proteasome
for degradation by autophagy. Additionally, it is described to interact with the autophagic
effector protein LC3 and is degraded through an autophagy-lysosome pathway. Briefly,
p62 functions as a receptor for cargo that is degraded by autophagy. If autophagy induction
occurs, p62 is degraded in the autolysosome. In contrast, autophagy inhibitors cause the
accumulation of p62 and, in turn, inhibit the autophagic process, favoring the anticancer
activity of the proposed drugs [51].
Herein, we examined p62 protein level by Western blot that showed drastic accumu-
lated in combinations over single treatment that similar founded in vitro and in vivo results
(Figure 7I,II and Supplementary Figure S4I,II). Results showed that the synergistic effect of
combinatorial treatment modulates autophagic flux inhibition due to ATG4B inhibition that
disrupts enzymatic degradation of autophagosome cargo via autophagosome-lysosome
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fusion blockage. Furthermore, our cocktail therapy inhibits the late autophagy step and dis-
rupts the autophagic degradation process, blockage LC3-II turnover, and p62 degradation,
especially triple combinatorial treatments, was accompanied by dramatically accumulation
of LC3-II and P62 level (autophagosomes markers). Additionally, the inhibition of the
autophagic flux by CQ/TIC may sensitize cancer cells to DOX by increasing apoptosis
as a result of enhancing DNA Damage as we previously described that might produce
autophagic death of cancer cells.
The current data, consistent with the previous study, reported that the combination
treatment with DOX attenuates DOX-induced cardiotoxicity through increased apoptosis
due to enhancing DNA Damage [52] and decreased autophagy without reducing the
apoptotic efficacy of Dox in ovarian cancer cells [53].
It is well known that the most common carcinoma subtype based on glutathione
peroxidase3 (GPx3) expression, a key antioxidant protein which that is necessary for cellular
survival in the ascites tumor environment and protects against extracellular oxidative
stress sources, implicating GPx3 as an essential adaptation for metastasis across peritoneal
cavity [54]. However, GPX3 was revealed to be highly upregulated in epithelial cell
carcinoma [55]. Here, the blotting data showed that the protein expression of GPX3 was
decreased in case of combinations over single treatment as represented in results of in vitro
and in vivo models (Figure 7I,II and Supplementary Figure S4I,II), while such decrease can
be explained by the ability of CQ and or TIC to modulate oxidative stress and enhance
tumor sensitivity to ROS-generating DOX drug (Supplementary Figure S3).
Our data proposed that combination treatments might induce apoptosis through
ROS-mediated PI3K/AKT signaling pathway. Strikingly, GPX3 level was downregulated
by either single treatments or combined DOX with TIC and/or CQ. In this sense, our data
proved that DOX combination with CQ and/or TIC caused cellular redox status dysregula-
tion as judged by significantly reduced cytosolic GPX level. Therefore, PI3K/AKT signaling
pathway plays a vital role in the apoptosis process, especially in the ROS-mediated apop-
totic pathway [56,57].
Thus, loss of GPx response to oxidative stress in cancer cells may account for CQ and
or TIC ability to enhance tumor sensitivity to ROS-generating DOX drug favoring cellular
apoptosis. Our results confirmed that the combinatorial treatments induce apoptosis via
ROS-mediated PI3K/AKT signaling pathway. Nevertheless, furthers investigations on
other signaling pathways, in addition, the kinase screening assays should be performed
to gain more insights into the signal transduction inhibitions induced by combinatorial
treatments. This study, in agreement with Kansanen and his colleagues, who reported the
inhibition of PI3K/AKT signaling blocks estrogen-mediated Nrf2 activation, has suggested
that targeting this pathway could be useful in treating BRCA1-deficient tumors by sensi-
tizing them to elevated ROS levels and reported PI3K inhibitors had been used to inhibit
Nrf2 in cancer cells [58].
This was also consistent with the study of Vibet and his team workers who reported
that breast cancer GPX3 was decreased by DOX alone or docosahexaenoic cotreatment with
DOX compared to control cells and activity loss due to reduced GPx protein level, corre-
sponding to unchanged levels of mRNA [59], this combination augmented. DOX-resistant
breast cancer cells attributed to high LPO (Lipid peroxidation) owed to malondialdehyde
(MDA) accumulation [60]. It is plausible that increased levels of lipid and protein oxidation
were increased due to the imbalance between the pro and antioxidant enzymes increasing
cytostatic effects. We hypothesized that combination therapy of DOX with TIC/CQ may
modulate oxidative stress to exert cytostatic effects in cancer cells.
Our proposed mechanism may be attributed to the possibility of diminished GPX3
expression level that may be due to alternated NRF2 (nuclear factor erythroid 2-related
factor 2) and KEAP1 (Kelch ECH associating protein 1) expression levels and increased
the inducible nitric oxide synthase (iNOS) expression that reported by Kovács and his
colleagues [61]. While KEAP1 serves as a repressor protein that binds to Nrf2 and induces
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subsequent proteolysis of Nrf2 by the ubiquitin-proteasome pathway, further investigations
are still in demand.
The current data presented that the combination therapy more greatly decreased the
expression of Bcl-2 accompanied by upregulation of apoptotic markers as Bax, caspase
3, as well as the mitochondrial cytochrome C was significantly elevated in both in vitro
and in vivo treated groups with Dox alone or co-treated with CQ and TIC, based on
Western blot, qRT-TPCR, and ELISA analysis and decreased cell viability based on the
MTT assay. Overall, these results indicated that CQ and TIC at least partly exert their
synergistic anti-tumor activity with DOX in cancer cells through induction disruption of
the mitochondrial membrane, the release of cytochrome C, then activate caspase cascade
that might effectively exploit chemosensitizer cancer cells to DOX, thereby reducing the
toxicity and drug resistance.
Moreover, the alternation of ATG5 and Beclin-1 required for autophagosome formation
was dramatically elevated in triple combination therapy, indicating a decrease in autophagic
degradation that was concomitant with increased ATG5 and reduction ATG4B protein
levels, which measured by ELIZA assay as showed in Figure 8, showed that co-treatment
results may be attributed to aggregation of polyubiquitinated proteins in the cells.
These data are consistent with a recent study that reported CQ as an autophagic
inhibitor in combination with Sinoporphyrin sodium (DVDMS)-mediated photodynamic
therapy (PDT) enhanced expression of ATG7 and LC3-II compared with DVDMS-PDT
alone treated cells and potentiated the cytotoxicity via inducing apoptosis dependent
caspase 3/9 activation [62]. More evidence for Becl-1 accumulation is the destruction
of the lysosomal degradation pathway as non-specific targets inhibit autophagosome
and lysosomal fusion [63]. Additionally, this is in agreement with a previous study that
revealed that the inhibition of the PI3K/AKT/mTOR pathway causes the induction of Atg5,
Atg7, Atg12, and Beclin1; and the inhibition of Bcl-2, and ultimately induces apoptosis via
activation of caspases [64].
This is consistent with Figure 8I,II, which showed the effect of combinatorial treat-
ments on increasing apoptotic-related protein levels, including Caspase-3, Caspase-8, P53,
notably that triple combinatorial therapies reached the maximum elevation levels. In
contrast, the expression level of Bcl-2 (anti-apoptotic) protein was markedly decreased
significantly in triple combinatorial treatment, which revealed the maximum reduction
compared to the untreated cells. Moreover, the proliferation protein marker KI-67 is shown
to be diminished in reaction to DOX with CQ and/or TIC combinations, especially in triple
combination cocktail therapy compared to DOX.
These results suggest that these combinations might be promising antimetastatic or
anti-proliferative agents of cancer cells. This finding may be attributed to DOX-mediated
activation of the nuclear enzyme (poly (ADP-ribose) polymerase-1) (PARP-1) subsequent
cleavage of caspase-3 and PARP and ultimately proceeded to apoptosis [65,66].
Our combinatorial treatment output data in the current study revealed the suppression
of autophagy in cancer cells leads to apoptosis, thus stimulating anti-tumor activity as
described previously [67]. Additionally, consistent with the study, it is reported that the
AKT phosphorylation inhibition simultaneously stimulates caspase-3 cascade in A549
cells [68], and promotes caspase-3 resistance to EGFR inhibitor therapy in several lung
cancer cell lines (NSCLC) [69]. These findings provided a precise mechanism by which
TIC/CQ treatment suppresses cellular growth and aggressiveness by downregulation of
PI3K/AKT/mTOR signaling pathways. Hence, our data supported the idea that DOX with
CQ and/or TIC may serve as a promising anti-tumor combination treatment regarding
inactivation of PI3K/Akt signaling, impairing autophagic flux, leading to the accumulation
of autophagosomes, which promotes apoptosis in MCF-7 cancer cells as well as in the
bearing tumor mice model.
Pharmaceuticals 2021, 14, 254 16 of 29
Figure 8. The disparity of apoptotic, anti-apoptotic, autophagy markers. Bar diagrams showing apoptotic markers as
caspase-3, caspase-8, P53 (A), Bcl2, KI-67 as proliferation markers (B), ATG4B (C) and ATG5 (D) as autophagic markers of
MCF-7 cells (I) and MCF-7 Xenograft mice (II) treated with single or combinatorial treatments. The data are presented as
mean ± SE of at least three independent experiments. # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001 compared with
control (untreated group). + p < 0.05, ++ p < 0.01, +++ p < 0.001, ++++ p < 0.0001 compared with the DOX treated group.
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Emerging evidence from the current study suggests the crucial role of cocktail combi-
nation therapy in mitigating liver and kidney functions and improved antioxidant levels.
Owing to these chemical drug safety profiles, we measured the physiological condition of
mice, including liver and kidney functions and balance between oxidant and antioxidant
parameters. We observed that combination therapy dramatically mitigated liver functions
(ALT, AST, and ALP) and also alleviated kidney functions (urea and creatinine), and LDH
activity reflected the lipid peroxidation status in cardiac membranes as compared to DOX
treated group (Supplementary Tables S2 and S3).
These data propose CQ/TIC combination with DOX as a promising hepatoprotective
agent and their antioxidant activity synergistically avoids the hepatocellular and renal
damage initiation and development process exerting the antineoplastic effect of DOX
and ameliorates the ROS damage caused by each drug alone. The cotreated mice group
adopt specific protection from cellular damage and rescue balance of ROS and antioxidant
capacity, resulting in the combination of DOX with CQ and/or TIC. This comes following
the result obtained from other research studies [70]. This is consistent with a previous study
that reported DOX-combined CQ treatment improved liver function than DOX treated
alone, and underscored its antioxidant activity, which protects proteins from free radicals
formed by DOX [71].
Regarding the biochemical investigation, results showed an increase in hepatic antiox-
idant status that was revealed by elevation of GPX, GST, CAT activities, and TAC levels
(Supplementary Table S4). The remarkable reduction in oxidative stress markers (levels of
the lipid peroxidation biomarker MDA, lipid hydroperoxide, conjugated dienes, and % of
hepatic DNA damage) (Supplemetary Table S5) was observed in the case of combinations
over single treatment or non-treated tumor-bearing mice. While the elevated level of lipid
peroxidation is concomitant with the decrease in reduced GPX, which indicates oxidative
stress that provides evidence of the relationship between LPO and tissue damage attributed
as described previously [72,73].
Moreover, oxidative stress and detoxification parameters including Arylsulphatase
(A and B), Arylestrase, and paraoxonase were extensively reduced in combination-treated
mice groups, indicating the improvement and ameliorated antioxidant levels and reduced
hepatic oxidative stress markers implying the burden of less oxidative combination drugs
as compared with DOX-treated groups (Supplementary Table S6). These findings revealed
the potential antioxidant effect of CQ and/or TIC in combination with DOX that alleviates
oxidative stress of DOX alone or untreated groups, and these data are in agreement
with a previous study that reported the DOX deactivation diminishing and restriction of
DOX efflux from cancer cells decreased antioxidant defense of cancer cells [35,74]. The
antioxidant effect of these combinations may prevent the associated free radical damage
generated by cancer and balanced by the antioxidant action of non-enzymatic antioxidants
as well as antioxidant enzymes [75].
2.7. Alleviation of Pathological Features Changes via Synergistically Combinatorial Treatments—
In Vivo Model
Histopathological assessment exhibited the lethal impact of DOX on liver tissue of
MCF-7 tumor-bearing mice and the competency of either CQ and/or TIC to ameliorate
this effect (Supplementary Figure S5). The full scope regarding CQ and TIC’s ability to
ameliorate the induced toxic effect of both DOX and oxidative stress of tumor cells on
liver tissues supported by those obtained by [71] confirmed that the CQ enhances the
antineoplastic effect of DOX and reduces its toxicities.
The ameliorative effect of combination treatments on histopathological changes of
mammary tumor gland and consecutive sections of xenograft MCF-7 tumors was investi-
gated as showed in (Supplementary Figure S6I,II). The immunoreaction changes of ERα
in ducts of the mammary gland and consecutive sections of the fibromuscular stroma of
xenograft tumors were investigated by immunohistochemical (IHC) analysis as showed in
(Supplementary Figure S7) and (Figure 9) respectively.
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Figure 9. Immunohistochemical analysis of ER- α imunostaining of xenograft tumors the mammary gland fibromuscular
stroma consecutive sections in different mice groups. The xenografted tumors were harvested and immunostained with the
anti-ERα antibody. (A)—MCF-7 xenograft: A photomicrograph of a section in the mammary gland of the control group
showing a strong ERα -positive nuclear and/or cytoplasmic immunoreaction in the form of a brown color in the cells of
the fibromuscular stroma. (B)—MCF-7 xenograft/DOX: A photomicrograph of a section in the mammary gland of DOX
treated group was apparently slightly same intense of ERα nuclear and/or cytoplasmic in the cells of the fibromuscular
stroma and morphometric analysis of ER-a-positive cells showed a non-significant increase when compared with the control
group. (C)—MCF-7 xenograft/CQ: A photomicrograph of a section in the mammary gland of CQ treated group was
apparently moderately differentiated tubular tumors and displayed moderate of an ERα nuclear intense and less intense of
cytoplasmic ERα in the cells of the fibromuscular stroma compared with the control group, (D)—MCF-7 xenograft/TIC:
A photomicrograph of a section in the mammary gland of TIC treated group was apparently moderate differentiated
tubular tumors and displayed moderate intense of an ERα nuclear intense and less intense of cytoplasmic ERα in the cells
of the fibromuscular stroma compared with the control group. (E)—MCF-7 xenograft/DOX + CQ: A photomicrograph
of a section in the mammary gland of DOX/CQ treated group was apparently moderate differentiated tubular tumors
and displayed less intense of an ERα nuclear and cytoplasmic intense of ERα in the cells of the fibromuscular stroma
compared with the control group. (F)—MCF-7 xenograft/DOX + TIC: A photomicrograph of a section in the mammary
gland of DOX/CQ treated group was apparently moderate differentiated tubular tumors and displayed less intense of an
ERα nuclear and cytoplasmic intense of ERα in the cells of the fibromuscular stroma compared with the control group.
(G)—MCF-7 xenograft/DOX + CQ + TIC: A photomicrograph of a section in the mammary gland of DOX/CQ/TIC treated
group was apparently developed poorly differentiated tumors showing almost slightly loss of ERα intense in the cells of the
fibromuscular stroma compared with the control group 50 µm.
Indeed, the histopathological data showed that the tumor cells exhibited high mi-
totic features as expected. Otherwise, it reduced in TIC alone or in combination with
DOX, and the breast and peritoneum tissues were found to be orderly arranged and rep-
resent the features of normal breast acini were found than DOX treated group, which
exhibited more dilated, necrotic, and calcified tumor cells. Apoptotic activity was also
higher in combination-treated groups, and a reduced level of angiogenesis was observed
(Supplementary Figures S6II and S7).
Nevertheless, because of immunohistopathological changes of ER-α in ducts of mam-
mary glands, a percentage of cell staining was observed. Overall, the combination of DOX
with CQ and/or TIC resulted in reducing staining intensity (brown color) that reflects lower
protein expression of ERα in the treated mammary tumors (Figure 9), and these data are
consistent with a previous study that reported that the proliferative Ki67 marker staining
by IHC analysis was reduced by cotreatment of DOX with withaferin A (Autophagic flux
inhibitor) [76].
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3. Materials and Methods
3.1. In-Silico Docking Study
The active crystal structures of ATG4B (PDB ID 2Z0D) and human PI3Kα (PI3 Kinase
p110α structure, PDB ID 2RD0 crystal structure with nSH2 domain mediate PI3K functions
through a-loop dynamics) and PI3Kγ (PDB ID: 1E8X crystal structure with ATP modeled),
were retrieved from the protein databank. (https://www.rcsb.org/structure/2z0d, https://
www.rcsb.org/structure/2RD0, https://www.rcsb.org/structure/1E8X; accessed on 7 July
2019). PubChem’s database uses the 3D chemical structures of Doxorubicin, Chloroquine,
and Tioconazole. Auto Dock 4 was used for docking accounts; then the Molecular Docking
Server (https://www.dockingserver.com accessed on 7 July 2019) was used [14], Protein
structures and the selected drugs were prepared as previously described [77].
3.2. Chemicals and Pharmaceuticals
Adricin (doxorubicin HCl injection, 2 mg/mL) was purchased from EIMC United
Pharmaceutics, Cairo, Egypt. Tioconazole (1-[2-[(2-Chloro-3-thienyl) methoxy]-2-(2, 4-
dichlorophenyl) ethyl]-1H-imidazole), Chloroquine diphosphate salt (N4-(7-Chloro-4-
quinolinyl)-N1, N1-dimethyl-1, 4-pentanediamine diphosphate salt) were purchased from
Merck KGaA, Darmstadt, Germany.
3.3. In Vitro Experiments
3.3.1. Cell Culture and Cytotoxicity Assay
Human MCF-7 cells and human normal epithelial cells (WISH) were cultured in
DMEM medium containing 10% fetal bovine albumin. All cells were provided by the
National Cancer Institute, Cairo University, Egypt. Cells were treated with the selected
drugs DOX, CQ, and TIC at different concentrations of 0–100 µM for 48 h. At standard
conditions. The cytotoxicity assay was performed using 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl-tetrazolium bromide (MTT) colorimetric assay according to previously published
protocol [78]. The concentration of drug inhibiting 50% of cells (IC50) was obtained using
GraphPad (Prism) statistic software version 6 [2].
3.3.2. The Combination Index (CI)
Combined treatments were analyzed using the Chou-Talalay protocol for dose effects.
The drug-drug interaction type was identified via combination index (CI) using compusyn
software. Synergism between tested agents indicates when a CI is less than 1, additively CI
equals 1, and antagonism CI is greater than 1 [79].
3.3.3. Experimental Design
MCF-7 cells were divided into 3 groups; (1) untreated cells; (2) single treated cells (this
group was divided into 3 subgroups; cells treated with IC50 for each of DOX, CQ, TIC);
(3) combined treated cells (It was divided into 3 subgroups according to the ratio of IC50
of the following drugs; DOX + CQ (1:2), DOX + TIC (1:6), DOX + CQ + TIC (1:1:1), that
showed the highest cytotoxic effect on cancer cells and the lowest CI with DOX dose; was
subjected for further molecular and biochemical investigations.
3.4. In Vivo Experiments
3.4.1. In Vivo Cytotoxic Activity in Xenografting Mice Model Induced by MCF-7 Cells
Female healthy BALB/c mice aged approximately 4–6 weeks and weighted about
15–20 g were purchased from the National Cancer Institute (Cairo University, Egypt). The
mice were housed under optimum temperature (23–25 ◦C, relative humidity 55%) with
free access to drinking water and food.
BALB/c mice were injected intraperitoneal route (i.p.) with 30 mg/kg immunosup-
pressant cyclosporine A (CsA) [80], every day for seven days, and it was injected with
60 mg/kg cyclophosphamide (CTX) subcutaneously route (SC) for two days (every other
day) before their injection with MCF-7 cells [81]. In addition, all mice were injected in-
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tramuscularly route (IM) with a hormonal mixture containing 1:1 volume of synthetic
17β-Estradiol (Cidodian Depot) (equaling to 1 mg/kg estradiol valerate) and estrogen
(Folon, 0.01 mL/kg body weight) for two successive days before MCF-7 cells injection to
promote tumor growth then the hormonal mixture injection continues until tumor for-
mation once weekly [82,83]. To establish in vivo model of breast cancer; human breast
cancer cell line cells (MCF-7) that harboring mouse mammary tumor virus (MMTV) were
grown into DMEM + 10% FBS, 1% penicillin/streptomycin, and 10 mg/mL insulin. Then
the trypsinized cells were washed with serum-free medium twice before its resuspension
into the matrigel-added serum-free medium (1:1). Each immunosuppressed mouse was
injected with (2 × 106 tumor cells/0.2 mL) orthotopic intradermally [14,84] into the 4th
mammary fat pad. When the tumor size grew up to approx. ~150–250 mm3, the mice were
randomly divided into different groups (according to experimental design). DOX and CQ
were dissolved in sterile PBS to prepare an appropriate experimental dose, while 1mg of
TIC was dissolved in 0.1% dimethyl sulfoxide DMSO as stock solutions and then diluted
to the appropriate doses in sterile PBS before the experiment.
3.4.2. Experimental Design of MCF-7 Tumor Development In Vivo Model
After injecting mice with cells, during the experiment tumor sizes were measured
using a digital caliper with a vernier to reach a tumor size of 150–250 mm3; the mice were
randomly divided into eight groups (15 mice per group) divided as follows: GPI: Naïve
(Control healthy mice injected with 0.2 mL of saline), GPII: MCF-7 group; (injected with
2 × 106 MCF-7 cells.), GPIII: DOX group (MCF-7 cells and DOX (2 mg/Kg; i.p.) [85] once
every 3 days, GPIV: CQ group (MCF-7 cells and CQ (50 mg/Kg; i.p.) [19] once every three
days. GPV: Tioconazole (TIC) (MCF-7 cells and TIC (60 mg/Kg.) [23] once every three days.
GPVI: DOX and CQ (MCF-7 cells and DOX and CQ) once every three days. GPVII: DOX
and TIC (MCF-7 cells and DOX and TIC) once every three days. GPVIII: DOX and TIC and
CQ (MCF-7 cells; i.p. and DOX and CQ and TIC) once every three days, Each treatment
was given in cycles; 2 times/week for 43 days [86] from tumor inoculation. Tumor volume
(mm3) [87] and body weight were measured every 7 days until animals were anesthetized
and sacrificed. After two weeks of treatment, all mice were euthanized under anesthesia
via Matrx VMS anesthesia machine (Midmark Corporation) by continuous inhalation of
CO2, 2% isoflurane gas for 5–10 min, Tumor inhibition rate (%) was determined [88].
At the end of the experiments, blood samples were collected to obtain serum and kept
at −20 ◦C until biochemical analysis. The first parts of each liver tissue and mammary
glands tumor tissue were excised and preserved at −80 ◦C. Mammary glands tumor tissue
of treated mice was homogenized and isolated as previously published protocols [89,90]
and subjected for molecular and biochemical studies, but other parts of fresh samples were
prepared for flow cytometry analysis. At the same time, liver tissue was homogenized for
enzymatic biochemical assays.
The second parts of liver tissue and mammary glands tumor tissue were washed with
isotonic saline and fixed in (10%) buffer formalin for histopathological assessment. Besides, the
immunohistochemical investigation was carried out for tumor tissue of mammary glands [91].
3.5. Genotoxicity Detection Using the Comet Assay
Comet assay was conducted to investigate the impact of treated MCF-7 cells and treated
isolated mammary tumor single cells on nuclear DNA damage by measuring tail length
(µm) compared with untreated cells as previously described [92,93]. Fluorescent microscopy,
Gel Red stain (red fluorescence), and Komet 5 image analysis software were used.
3.6. DNA Fragmentation Assay Using Diphenylamine (DPA) Reagent
The Diphenylamine assay was used to measure degraded DNA [94]. Briefly, the
treated MCF-7 and mammary cells were collected in the lysis solution (10 mM Tris base,
1 mM EDTA and 0.2% Triton X-100, pH 8.0) centrifuged at 14,000× g for 15 min at 4 ◦C.
The fragmented DNA in the supernatant and the intact DNA in the pellets were separated
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and evaluated using diphenylamine reagent and incubated the samples overnight at 4 ◦C.
Finally, optical density was read with a spectrophotometer reader at 600 nm.
3.7. Annexin V FITC Assay
MCF-7 and isolated mammary tumor cells were washed twice with cold PBS, then
1 × 106 cells/mL were suspended in 1X Annexin-binding buffer (0.01 M HEPES, pH 7.4,
0.14 M NaCl and 2.5 mM CaCl2). Then, 25 µL Annexin V-FITC/propidium iodide (PI)
solution was added to 100 µL of suspended tumor cells, and then cells were incubated
at RT for 15 min in the dark [95]. After incubation, 400 µL binding buffer was added.
The cells were analyzed within one hour by FACS Calibur flow cytometer (Becton Dick-
inson Biosciences, San Jose, CA, USA) using the Cell Quest™ software and analyzed by
Kaluza software [96].
3.8. Autophagy Determination Using Flow Cytometry Analysis
The autophagosome level of MCF-7 treated cells, and isolated tumor cells of the
mammary gland [97] were analyzed by flow cytometry using a proprietary fluorescent
autophagosome marker (lex = 333/lem = 518 nm) of autophagy assay kit (#MAK138S,
Sigma Aldrich, St. Louis, MO, USA) and analysis was performed following manufacturer
protocol [98]. Briefly, treated cells were washed with ice-cold PBS twice. Then, the cells
were stained with autophagy dye (1 µL per 100 µL sample) and then subjected to incubation
incubate for 30 min in the dark. According to the manufacturer’s instructions, the cells
were examined with a flow cytometer (Applied Biosystems, Foster City, CA, USA).
The results yielded as mean fluorescence intensity (MFI) measure when autophagic
vesicles were generated, then it was expressed as autophagy activity factor (AAF) calculated
according to the equation: AAF (%) = 100 × ((MFItreated − MFIcontrol)/MFItreated). The
autophagy intensity was expressed as AAF, a parameter assessed based on MFI detected
and reflected the number of accumulated autophagosomes present in an analyzed cell
population under particular treatment conditions and control cell populations. Where
MFI = mean fluorescence intensity. AAF is a quantitative method commonly employed to
quantify autophagic flux that is adopted to measure the level of autophagic accumulation
within a cell population in the present study [99].
3.9. Gene Expression Analysis by Quantitative Real-Time PCR (qPCR)
The qPCR was carried out on treated MCF-7 cells and mammary tumor tissue to assess
expression levels for Bax, p53, caspase-3, caspase-9, Cytochrome C, Bcl2, Beclin-1, PI3K,
AKT, and ATG7 genes [100]. Briefly, RNA was extracted from the tumor cells and MCF-7
cells using RNeasy® Plus Mini kit (Qiagen, Hilden, Germany), RNA samples were reverse
transcribed into cDNA using Revert Aid H Minus Reverse Transcriptase kit (Thermo Fisher
Scientific, Waltham, MA, USA) following the manufacturer’s protocol. The real-time PCR
assay was performed by Power SYBR Master Mix (Thermo Fisher Scientific, USA) using
a PCR machine (Applied Biosystems 7500 system, Foster City, USA) [101]. GAPDH was
used as an internal control. The critical threshold (Ct) of the target gene was normalized
with (Ct) of GAPDH using (2−∆∆CT) method [101]. Estimation was based on fold change in
2−∆∆CT of gene expression in treated groups relative to the control group. Primer sequences
used in real-time PCR are listed in Tables 4 and 5.
3.10. Immunoblotting Analysis
Western blotting was performed to cell lysate of mammy tumor cells, or MCF-7
cells were performed according to the protocol published [102,103] using specific primary
antibodies to the following proteins LC3, p62, Phospho-PI3K, Phospho-AKT, Phospho-
mTOR, Bax, Bcl-2, GPX-3, PARP and β-Actin with the following cat. no.# (2775, Ab205718,
ab182651, ab81283, 29771, 2772, ab196495, sc-58361, 9542 and 4967), respectively.
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Table 4. Human primers sequences used in real-time PCR.







Bax NM_001291428.2 CCTGTGCACCAAGGTGCCGGAACT CCACCCTGGTCTTGGATCCAGCCC 426–524 99
P53 NM_000546.6 TAA CAG TTC CTG CAT GGG CGGC AGG ACA GGC ACA AAC ACG CACC 856–976 121
Caspase 3 NM_001354777.2 TTA ATA AAG GTA TCC ATG GAGAAC ACT
TTA GTG ATA AAA ATA GAG TTC
TTT TGT GAG 138–1031 849
Caspase 9 NM_001229.5 GAGGGAAGCCCAAGCTCTTT CACTGGGTGTGGGCAAACTA 842–1033 192
Cytochrome C NM_018947.6 TACTCTTACACAGCCGCCAATA AGTCTGCCCTTTCTTCCTTCTT 208–352 145
Bcl2 NM_000633.3 AGG AAG TGA ACA TTT CGG TGAC GCT CAG TTC CAG GAC CAG GC 2481–2626 146
Beclin-1 NM_001313998.2 GGTGTCTCTCGCAGATTCATC TCAGTCTTCGGCTGAGGTTCT 359–479 121
PI3K NM_006218.4 GGTTGTCTGTCAATCGGTGACTGT GAACTGCAGTGCACCTTTCAAGC 2832–2939 108
AKT NM_001014431.2 GTGCTGGAGGACAATGACTACG AGCAGCCCTGAAAGCAAGGA 1302–1495 194
ATG7 NM_001136031.3 ATGATCCCTGTAACTTAGCCCA CACGGAAGCAAACAACTTCAAC 739–852 114
GAPDH NM_001256799.3 TGGACCTGACCTGCCGTCTA CCCTGTTGCTGTAGCCAAATTC 905–1147 243
Table 5. Mouse primer sequences used in real-time PCR.







Bax NM_007527.3 GGCTGGACACTGGACTTCCT GGTGAGGACTCCAGCCACAA 535–669 135
P53 NM_001127233.1 ACAGTCGGATATCAGCCTCG TTTTTTGAGAAGGGACAAAA 178–452 275
Caspase 3 NM_001284409.1 GACCATACATGGGAGCAAGT CCTTCATCACCATGGCTTAGA 283–600 318
Caspase 9 NM_001277932.1 AGTTCCCGGGTGCTGTCTAT GCCATGGTCTTTCTGCTCAC 1091–1242 152
Cytochrome C NM_007808.5 GAGGCAAGCATAAGACTGGA TACTCCATCAGGGTATCCTC 233–365 133
Bcl2 NM_009741.5 TTCGCAGAGATGTCC AGTCA TTCAGAGACAGCCAGGAGAA 1735–2054 320
Beclin-1 NM_001359819.1 CTGCACAGGGAACACAGCAA GCCAGCGGCTATGAGAGAAG 285–390 106
PI3K NM_001024955.2 GGCAGAAGAAGCTGAACGAG GCAATAGGTTCTCCGCTTTG 1301–1447 147
AKT NM_001165894.1 ACTCATTCCAGACCCACGAC AGTCCAGGGCAGACACAATC 1014–1157 144
ATG7 NM_001253717.2 ATGCCAGGACACCCTGTGAACTTC ACATCATTGCAGAAGTAGCAGCCA 1497–1846 350
GAPDH NM_001289726.1 TGTGTCCGTCGTGGATCTGA CCTGCTTCACCACCTTCTTGA 803–879 77
3.11. Detection of Apoptotic, Anti-Apoptotic, and Autophagic Markers Protein Levels
(ELISA Assay)
The cell lysate obtained from treated MCF-7 cells and mammary tumor tissue was
performed by cell fractionation, and the total proteins were extracted to measure the levels
of caspase-3, caspase-8, P53, Bcl2, and KI-67 proteins (apoptotic and anti-apoptotic markers),
ATG4B, and ATG5 proteins levels (autophagic markers) using Bradford assay kit (Bio-
Rad Laboratories, Inc., Hercules, CA, USA). The isolated proteins were measured using
human ELISA Kits for Caspase-3 (cat no: 15511487, Thermo Fisher Scientific, UK), caspase
8 (eBioscience, BMS2024TEN), P53 (cat no: BMS256, Thermo Fisher Scientific, UK), Bcl-
2 (cat no: BMS244-3, Thermo Fisher Scientific, Basingstoke, UK), KI-67 (cat no: 14507,
PathScan®CST, Danvers, MA, USA) ATG4B (cat no: MBS7226180, My Biosource, San
Diego, CA, USA) and ATG5 (cat no: MBS2602759, My Biosource, USA) according to the
manufacturers’ instructions. Mouse ELISA Kits were used for Caspase-3 (cat no: CSB-
E08858m, Cusabio, Wuhan, China), Caspase-8 (cat no: (CSB-E08862H, Cusabio, China), P53
(cat no: ab224878, Abcam, Cambridge, MA, USA), Bcl-2 (cat no: ab227899, Abcam, USA),
KI-67 (CSB-EL014597MO, Cusabio, China) and ATG4B (cat no: MBS7209286, My Biosource,
USA), ATG5 (cat no: MBS7227851, My Biosource, USA) according to the manufacturers’
instructions. According to the manufacturer’s instructions, the standard curves were drawn
according to each kit, and the reaction products were measured at 450 nm using a microplate
reader (Tecan sunrise microplate reader, Awareness Technology Inc., Palm City, FL, USA).
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3.12. Intracellular ROS Production Measurement
2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) fluorescence assays were per-
formed to evaluate the ability of tested drugs induced ROS against MCF-7 cell lines. Briefly,
MCF-7 cells (1 × 105cells/well) were treated with tested drugs for 24 h. Then, the cells
were washed five times with cold PBS. Subsequently, the cells were processed, and the
DCF concentration in cell lysates was estimated as described previously; treated groups
were plotted against mean DCF fluorescence [104].
3.13. Biochemical Measurements
Serum parameters involving ALT and AST activities, total protein, albumin, and urea
levels were measured by commercial kits (Diamond-Diagnostics, Cairo, Egypt). Serum ALP
activity was assessed using a commercial kit (Bio Diagnostic, Giza, Egypt). LDH activity,
serum creatinine concentration, and serum total lipids concentration were measured by
commercial kits (Bio Diagnostic, Egypt) [105,106].
Hepatic tissues of mice were excised and washed with isotonic saline and divided into
two parts. The first part was stored in −20 ◦C for investigating antioxidant and oxidative
parameters. The liver was dissected out after transcardial perfusion with ice-cold saline.
The whole liver was blot dried, weighed, then 10% of tissue homogenate was prepared with
ice-cold potassium chloride (150 mM) by homogenizer (Remi-Egypt). In brief, the tissue
homogenate was used in enzymatic assays, which are involved in the antioxidant defense
system, including determination of total thiol content [107], Glutathione peroxidase (GPx)
activity [108], Glutathione-S-transferase (GST) activity [109], Catalase (CAT) activity [110],
total antioxidant capacity (TAC) levels [111] and thioredoxin reductase activities [106].
Additionally, we evaluated oxidative stress markers included MDA level [112,113],
and Conjugated dienes [114]. Moreover, we estimated the toxicity biomarkers included
Arylsulphatase A (ASA) activity, Arylsulphatase B (ASB) activity [115], Arylestrase and
paraoxonase activities [106,116] and hepatic DNA Fragmentation (%) using diphenylamine
(DPA) assay [117,118]. After euthanasia, the second part of the liver was washed with
isotonic saline and fixed in (10%) buffer formalin for histopathological assessment. Mam-
mary gland of MCF-7 mice model was isolated [89,90], prepared for histological and
immunohistochemical examinations [91].
3.14. Histopathological and Immunohistochemistry (IHC) Analysis
Liver and mammary gland tissue sections were fixed in 10% neutral buffered formalin,
paraffin-embedded tissues were cut at 5 µm thickness and stained with hematoxylin and
eosin, then examined under a light microscope [119]. The tissue sections were identified
for immunohistochemistry using the avidin-biotin-immunoperoxidase method by reacting
with anti-ERa primary antibodies (Santa Cruz Biotechnology, Inc). The anti-ER was used
at 1:50 dilution. Slides were counterstained with Mayer’s hematoxylin, rinsed in running
tap water for 10 min, dehydrated into 95% ethanol for 1 min, 100% ethanol two times
for 3 min, cleared in xylene two times for 5 min, and cover-slipped using a permanent
mounting media. The positively stained area is brown in color, was observed against the
negatively stained region [120]. Finally, the immune-stained tissues were photographed by
Leica ICC50 HD microscope camera [121].
3.15. Statistical Analysis
The experimental data were expressed as Mean ± SE; the significance among the vari-
ous treated groups and control was analyzed using one-way ANOVA followed by Tukey
analysis by GraphPad prism software 7 (San Diego, CA, USA), acceptable significance was
recorded when the p-value was <0.05.
4. Conclusions
The current study spotlights the ability of DOX/CQ and/or TIC combination strategy
to effectively increase DOX’s antitumor activity efficiency. We showed that DOX combi-
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nation therapy with CQ and/or TIC inactivates the PI3K/Akt/mTOR signaling pathway,
in addition to ATG4B inhibition which impairs autophagic flux, leading to accumulated
autophagosome-dependent cell apoptosis.
The study also highlights PI3K/AKT pathway as a therapeutic target with DOX-
induced cytotoxicity. Based on our docking studies, apoptotic cell death induction, and
autophagic flux inhibition, the combination of CQ and/or TIC with DOX serves as a
promising antitumor strategy with synergistic interaction that stimulates the autophagic
cell death in conjunction with apoptotic cell death triggered by ROS, caspase-mediated
cellular apoptosis showed an increased cytotoxic effect on cancer cell growth with decreased
DOX side effects and low toxicity on normal cells.
However, the potentiality of the current combination as a suggested alternative ther-
apy against tumor proliferation via the targeted autophagic and apoptotic pathways must
be confirmed. Based on our data, DOX combination with CQ and/or TIC exhibited multi-
ple effects against PI3K/AKT/mTOR in autophagy regulation more than ATG4B inhibition,
hoping to provide some inspirations. However, further analysis on different types of
cells is required to fully understand the functional role of multiple pathways targeting
combination therapeutic strategies.
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in each group, Figure S6I-II: Histopathological investigation of mammary gland and consecutive
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